Incidence of myeloid neoplasms post PARPi in patients with ovarian cancer enrolled in pivotal randomized clinical trials
| First-line maintenance setting | |||
| SOLO1 (OLA vs PBO; BRCAm) | PRIMA (NIRA vs PBO) | ATHENA-MONO (RUCA vs PBO) | PAOLA1 (OLA+BEVA vs PBO+BEVA) |
| Primary analysis: 1% vs 0%5 | Primary analysis: 0.2% vs 0%6 | Primary analysis: 0.5% vs 0%7 | Primary analysis: 1.1% vs 0.4%8 |
| 7-year FU: 1.5% vs 0.8%50 | 3.5-year FU: 1.2% vs 1.2%51 | 5-year FU: 1.7% vs 2.2%52 | |
| Platinum-sensitive recurrent maintenance setting | |||
| SOLO2 (OLA vs PBO; BRCAm) | NOVA (NIRA vs PBO) | ARIEL3 (RUCA vs PBO) | OReO (OLA rechallenge vs PBO) |
| Primary analysis: 2.1% vs 4%11 | Primary analysis: 1.4% vs 1.1%10 | Primary analysis: 1% vs 0%9 | Awaited53 |
| 6-year FU: 8% vs 4%13 | 5.5-year FU: 3.5% vs 1.7%12 | 6-year FU: 3.8% vs 3.2%48 | |
BEVA, bevacizumab; BRCAm, BRCA-mutated patients; FU, follow-up; NIRA, niraparib; OLA, olaparib; PARPi, poly (ADP-ribose) polymerase inhibitor; PBO, placebo; RUCA, rucaparib.